Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile

Journal of Controlled Release

Volumn 139, Issue 3, 2009, Pages 190-196

  Murciano, Juan Carlos ^a,b   Higazi, Abd Al Roof ^b   Cines, Douglas B ^b   Muzykantov, Vladimir R ^b  

^a CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Delivery vehicle; Erythrocyte; Fibrinolysis; Thrombosis; Urokinase

Indexed keywords

DELIVERY VEHICLE; ERYTHROCYTE; FIBRINOLYSIS; THROMBOSIS; UROKINASE;

BLOOD; DISSOLUTION; DRUG INTERACTIONS; ENZYME INHIBITION; HEMOGLOBIN OXYGEN SATURATION; RATS;

ENDOTHELIAL CELLS;

PROUROKINASE; UROKINASE RECEPTOR;

ARTICLE; BINDING AFFINITY; BIOCOMPATIBILITY; BIOTINYLATION; CELL ADHESION; CIRCULATION TIME; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; ENDOTHELIUM CELL; ERYTHROCYTE; FIBRINOLYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOSIS PREVENTION; TISSUE DISTRIBUTION;

ANIMALS; BIOTINYLATION; CELL ADHESION; CELLS, CULTURED; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG COMPOUNDING; ENDOTHELIAL CELLS; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HUMANS; PRODRUGS; PROTEIN BINDING; RATS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RECOMBINANT PROTEINS; THROMBOLYTIC THERAPY; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 70349335374     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.07.003     Document Type: Article

References (50)

1. Motlekar N.A., and Youan B.B. The quest for non-invasive delivery of bioactive macromolecules: a focus on heparins. J. Control. Release 113 (2006) 91-101
2. Martin M.E., Kloecker G.H., and Laber D.A. Argatroban for anticoagulation during cardiac surgery. Eur. J. Haematol. 78 (2007) 161-166
3. Spyropoulos A.C. Bridging of oral anticoagulation therapy for invasive procedures. Curr. Hematol. Rep. 4 (2005) 405-413
4. Selim M. Perioperative stroke. N. Engl. J. Med. 356 (2007) 706-713
5. Hertfelder H.J., Bos M., Weber D., Winkler K., Hanfland P., and Preusse C.J. Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting. Semin. Thromb. Hemost. 31 (2005) 426-440
6. Zhang R.L., Zhang L., Jiang Q., Zhang Z.G., Goussev A., and Chopp M. Postischemic intracarotid treatment with TNK-tPA reduces infarct volume and improves neurological deficits in embolic stroke in the unanesthetized rat. Brain Res. 878 1-2 (2000) 64-71
7. Reed G.L., Houng A.K., Liu L., et al. A catalytic switch and the conversion of streptokinase to a fibrin-targeted plasminogen activator. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 8879-8883
8. Yang V.C., Naik S.S., Song H., Dombkowski A.A., Crippen G., and Liang J.F. Construction and characterization of a t-PA mutant for use in ATTEMPTS: a drug delivery system for achieving targeted thrombolysis. J. Control. Release 110 (2005) 164-176
9. Cheng M.B., Wang J.C., Li Y.H., et al. Characterization of water-in-oil microemulsion for oral delivery of earthworm fibrinolytic enzyme. J. Control. Release 129 (2008) 41-48
10. Liu Y., Miyoshi H., and Nakamura M. Encapsulated ultrasound microbubbles: therapeutic application in drug/gene delivery. J. Control. Release 114 (2006) 89-99
11. Murciano J.C., Medinilla S., Eslin D., Atochina E., Cines D.B., and Muzykantov V.R. Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes. Nat. Biotechnol. 21 (2003) 891-896
12. Ganguly K., Krasik T., Medinilla S., et al. Blood clearance and activity of erythrocyte-coupled fibrinolytics. J. Pharmacol. Exp. Ther. 312 (2005) 1106-1113
13. Danielyan K., Ganguly K., Ding B.S., et al. Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator. Circulation. 118 (2008) 1442-1449
14. Nassar T., Haj-Yehia A., Akkawi S., et al. Binding of urokinase to low density lipoprotein-related receptor (LRP) regulates vascular smooth muscle cell contraction. J. Biol. Chem. 277 (2002) 40499-40504
15. Akkawi S., Nassar T., Tarshis M., Cines D.B., and Higazi A.A. LRP and alphavbeta3 mediate tPA activation of smooth muscle cells. Am. J. Physiol. Heart. Circ. Physiol. 291 (2006) H1351-1359
16. Higazi A.A., Mazar A., Wang J., et al. Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1. Blood. 87 (1996) 3545-3549
17. Bdeir K., Kuo A., Sachais B.S., et al. The kringle stabilizes urokinase binding to the urokinase receptor. Blood. 102 (2003) 3600-3608
18. Haj-Yehia A., Nassar T., Sachais B.S., et al. Urokinase-derived peptides regulate vascular smooth muscle contraction in vitro and in vivo. Faseb. J. 14 (2000) 1411-1422
19. Higazi A.A.-R., Aceto J.F., Kniss D., et al. Unesterified long chain fatty acids inhibit the binding of single chain urokinase to the urokinase receptor. Biochemistry 35 (1996) 6884-6890
20. Muzykantov V.R., Murciano J.C., Taylor R.P., Atochina E.N., and Herraez A. Regulation of the complement-mediated elimination of red blood cells modified with biotin and streptavidin. Anal. Biochem. 241 (1996) 109-119
21. Ganguly K., Goel M.S., Krasik T., et al. Fibrin affinity of erythrocyte-coupled tissue-type plasminogen activators endures hemodynamic forces and enhances fibrinolysis in vivo. J. Pharmacol. Exp. Ther. 316 (2006) 1130-1136
22. Magnani M., Rossi L., Fraternale A., et al. Erythrocyte-mediated delivery of drugs, peptides and modified oligonucleotides. Gene Ther. 9 (2002) 749-751
23. Chambers E., and Mitragotri S. Prolonged circulation of large polymeric nanoparticles by non-covalent adsorption on erythrocytes. J. Control. Release 100 (2004) 111-119
24. Hamidi M., Zarrin A., Foroozesh M., and Mohammadi-Samani S. Applications of carrier erythrocytes in delivery of biopharmaceuticals. J. Control. Release 118 (2007) 145-160
25. Millan C.G., Marinero M.L., Castaneda A.Z., and Lanao J.M. Drug, enzyme and peptide delivery using erythrocytes as carriers. J. Control. Release 95 (2004) 27-49
26. Chambers E., and Mitragotri S. Long circulating nanoparticles via adhesion on red blood cells: mechanism and extended circulation. Exp. Biol. Med. (Maywood). 232 (2007) 958-966
27. Gupta A.S., Huang G., Lestini B.J., Sagnella S., Kottke-Marchant K., and Marchant R.E. RGD-modified liposomes targeted to activated platelets as a potential vascular drug delivery system. Thromb. Haemost. 93 (2005) 106-114
28. Nikanjam M., Gibbs A.R., Hunt C.A., Budinger T.F., and Forte T.M. Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. J. Control. Release 124 (2007) 163-171
29. Elbayoumi T.A., and Torchilin V.P. Liposomes for targeted delivery of antithrombotic drugs. Expert. Opin. Drug. Deliv. 5 (2008) 1185-1198
30. Sakharov D.V., and Rijken D.C. Superficial accumulation of plasminogen during plasma clot lysis. Circulation. 92 (1995) 1883-1890
31. Plow E.F., Herren T., Redlitz A., Miles L.A., and Hoover-Plow J.L. The cell biology of the plasminogen system. Faseb J. 9 (1995) 939-945
32. Rabbani S.A., Mazar A.P., Bernier S.M., et al. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase. J. Biol. Chem. 267 (1992) 14151-14156
33. Husain S.S. Single-chain urokinase-type plasminogen activator does not possess measurable intrinsic amidolytic or plasminogen activator activities. Biochemistry. 30 (1991) 5797-5805
34. Urano T., de Serrano V.S., Gaffney P.J., and Castellino F.J. The activation of human [Glu1]plasminogen by human single-chain urokinase. Arch. Biochem. Biophys. 264 (1988) 222-230
35. Pannell R., and Gurewich V. Activation of plasminogen by single-chain urokinase or by two-chain urokinase-a demonstration that single-chain urokinase has a low catalytic activity (pro-urokinase). Blood. 69 (1987) 22-26
36. Zhang L., Strickland D.K., Cines D.B., and Higazi A.A. Regulation of single chain urokinase binding, internalization, and degradation by a plasminogen activator inhibitor 1-derived peptide. J. Biol. Chem. 272 (1997) 27053-27057
37. Higazi A., Cohen R.L., Henkin J., Kniss D., Schwartz B.S., and Cines D.B. Enhancement of the enzymatic activity of single-chain urokinase plasminogen activator by soluble urokinase receptor. J. Biol. Chem. 270 (1995) 17375-17380
38. Wang J., Mazar A., Quan N., Schneider A., and Henkin J. Plasminogen activation by pro-urokinase in complex with its receptor-dependence on a tripeptide (Spectrozyme plasmin). Eur. J. Biochem. 247 (1997) 256-261
39. Schwartz B.S., and Espana F. Two distinct urokinase-serpin interactions regulate the initiation of cell surface-associated plasminogen activation. J. Biol. Chem. 274 (1999) 15278-15283
40. Higazi A.A., Bdeir K., Hiss E., et al. Lysis of plasma clots by urokinase-soluble urokinase receptor complexes. Blood. 92 (1998) 2075-2083
41. Higazi A.A., Ajawi F., Akkawi S., Hess E., Kuo A., and Cines D.B. Regulation of the single-chain urokinase-urokinase receptor complex activity by plasminogen and fibrin: novel mechanism of fibrin specificity. Blood. 105 (2005) 1021-1028
42. Liu J.N., and Gurewich V. Fragment E-2 from fibrin substantially enhances pro-urokinase-induced Glu-plasminogen activation. A kinetic study using the plasmin-resistant mutant pro-urokinase Ala-158-rpro-UK. Biochemistry 31 (1992) 6311-6317
43. Gyetko M.R., Chen G.H., McDonald R.A., et al. Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. A murine transgenic model. J. Clin. Invest. 97 (1996) 1818-1826
44. Pedersen T.L., Yong K., Pedersen J.O., Hansen N.E., Dano K., and Plesner T. Impaired migration in vitro of neutrophils from patients with paroxysmal nocturnal haemoglobinuria. Br. J. Haematol. 95 (1996) 45-51
45. Sagnella S., Kwok J., Marchant R.E., and Kottke-Marchant K. Shear-induced platelet activation and adhesion on human pulmonary artery endothelial cells seeded onto hydrophilic polymers. J. Biomed. Mater. Res. 57 (2001) 419-431
46. Siedlecki C.A., Lestini B.J., Kottke-Marchant K.K., Eppell S.J., Wilson D.L., and Marchant R.E. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood. 88 (1996) 2939-2950
47. Simon S.I., and Goldsmith H.L. Leukocyte adhesion dynamics in shear flow. Ann. Biomed. Eng. 30 (2002) 315-332
48. Graham D.A., Huang T.C., Keyt B.A., and Alevriadou B.R. Real-time measurement of lysis of mural platelet deposits by fibrinolytic agents under arterial flow. Ann. Biomed. Eng. 26 (1998) 712-724
49. Konstantopoulos K., Kukreti S., and McIntire L.V. Biomechanics of cell interactions in shear fields. Adv. Drug. Deliv. Rev. 33 (1998) 141-164
50. Zaitsev S., Danielyan K., Murciano J.C., et al. Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis. Blood. 108 (2006) 1895-1902